STOCK TITAN

VIVUS to Host First Quarter Business Update and Financial Results Conference Call on Wednesday, May 6, 2020

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences earnings

CAMPBELL, Calif., May 01, 2020 (GLOBE NEWSWIRE) -- VIVUS, Inc. (Nasdaq: VVUS) today announced that it will report financial results and provide a business update for the first quarter of 2020 after the market close on Wednesday, May 6, 2020. The Company will host a conference call beginning at 4:30 p.m. ET / 1:30 p.m. PT the same day to review results and provide a business update.

To listen via webcast, please visit http://ir.vivus.com/, or by clicking here.

To listen via phone, please use the dial in information provided below.

Dial in Details:
Toll-Free: (877) 359-2916
International: (224) 357-2386
Passcode: 6939389

A webcast replay will be available on the VIVUS website for 30 days.

About VIVUS
VIVUS is a biopharmaceutical company committed to the development and commercialization of innovative therapies that focus on advancing treatments for patients with serious unmet medical needs. For more information about VIVUS, please visit www.vivus.com.

Forward-Looking Statements
Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as “anticipate,” “believe,” “forecast,” “estimate,” “expect,” “intend,” “likely,” “may,” “plan,” “potential,” “predict,” “opportunity” and “should,” among others. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. VIVUS does not undertake an obligation to update or revise any forward-looking statements. Investors should read the risk factors set forth in VIVUS’ Form 10-K for the year ended December 31, 2019 as filed on March 3, 2020, and as amended by the Form 10-K/A filed on April 29, 2020, and periodic reports filed with the Securities and Exchange Commission. VIVUS does not undertake an obligation to update or revise any forward-looking statements.

CONTACT:   
   
VIVUS, Inc.   Investor Relations: Lazar FINN Partners
Mark Oki   David Carey
Chief Financial Officer   Senior Partner
oki@vivus.com  david.carey@finnpartners.com 
650-934-5200   212-867-1768

VVUS

NASDAQ:VVUS

VVUS Rankings

VVUS Latest News

VVUS Stock Data

Pharmaceuticals: Other
Health Technology
Link
US
Campbell